GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
I

Immunovant IMVT · USD

Health Care · US listing · 🇺🇸 United States

Compare

35.15

+15.13%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2026

Net income

−$505.6m

FY2018FY2026

Free cash flow

−$407.3m

FY2018FY2026

Shareholders' equity

$852.6m

FY2018FY2026

Income statement

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Gross profit−$409,000−$377,000−$231,000−$1.3m−$1.2m−$998,000−$21,000——
Research and development$456.7m$360.9m$212.9m$160.3m$101.8m$68.6m$47.9m$25.7m$135.3m
Operating income−$532.9m−$438.2m−$270.2m−$208.3m−$156.8m−$108.1m−$65.7m−$450−$136.7m
Net income−$505.6m−$413.8m−$259.3m−$211.0m−$156.7m−$107.4m−$66.4m−$450−$136.7m
Diluted earnings per share-2.46-2.28-1.77-1.46-1.22-0.93-0.68-0.00-3.72

Balance sheet

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Total assets$957.6m$776.2m$666.7m$405.8m$515.6m$412.5m$109.4m$405,000$113,170
Cash and short-term investments$902.1m$714.0m$635.4m$376.5m$493.8m$400.1m$100.6m$325,000—
Total liabilities$105.0m$68.8m$49.0m$43.3m$45.7m$21.0m$15.3m$380,448$1.6m
Debt$72,000——————$300,000—
Shareholders' equity$852.6m$707.4m$617.8m$362.5m$469.8m$391.5m$94.1m$24,552−$1.5m
Shares outstanding206m182m147m145m129m115m98m41m37m

Cash flow

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash from operations−$407.3m−$375.9m−$214.2m−$188.2m−$106.1m−$83.3m−$53.4m−$28.5m−$128.3m
Capital spending−$8,000−$759,000−$360,000−$197,000−$254,000−$210,000−$31,000−$52,000−$52,000
Free cash flow−$407.3m−$376.6m−$214.6m−$188.4m−$106.4m−$83.5m−$53.4m−$28.6m−$128.3m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue$7.1m————$160,000——
Gross profit$7.1m—−$101,000−$105,000−$107,000$80,000−$99,000−$89,000
Operating income−$153.2m−$159.6m−$114.4m−$131.8m−$127.2m−$113.8m−$114.3m−$115.7m
Net income−$153.2m−$147.9m−$110.6m−$126.5m−$120.6m−$106.4m−$111.1m−$109.1m
Diluted earnings per share-0.75-0.72-0.61-0.70-0.66-0.59-0.76-0.74
Cash from operations−$124.0m−$95.0m−$92.0m−$102.0m−$117.0m−$110.0m−$100.0m−$88.0m
Total assets$852.5m$957.0m$1.05bn$583.0m$661.4m$776.2m$420.9m$515.7m
Cash and short-term investments$797.8m$902.1m$994.5m$521.9m$598.9m$714.0m$374.7m$472.9m
Debt—$72,000———$98,000$23,000$47,000
Shareholders' equity$735.4m$852.6m$986.1m$519.7m$608.5m$707.4m$352.6m$449.1m

Financial ratios

Data as of 15 Oct 2026

FY2026FY2025FY2024FY2023FY2022FY2021FY2020
Return on equity-59.3%-58.5%-42.0%-58.2%-33.4%-27.4%—
Return on assets-52.8%-53.3%-38.9%-52.0%-30.4%-26.0%—
Free cash flow yield-7.1%-7.4%-5.2%-4.7%-3.0%-2.6%—
Earnings growth22.2%59.6%22.9%34.6%45.9%61.8%—
Current ratio9.09x11.16x13.70x9.34x11.52x21.79x—
Debt to equity0.00x0.00x0.00x0.00x0.00x0.00x—
Equity ratio89.0%91.1%92.7%89.3%91.1%94.9%—
Interest coverage——-5.19x-15.90x-239.41x—-105.07x
Buybacks as a share of market value-13.2%-23.5%-1.7%-12.4%-11.8%-17.5%—

Growth per year

Compound annual rate

3 years5 years10 years
Operating income36.8%37.6%—
Net income33.8%36.3%—

Valuation history

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Price to earnings-12.2-11.2-14.0-28.9-14.6-9.1-24.5-519742.5

Market value over time

28 Jun 2019 to 14 Oct 2026, in USD

$29.4m$5.73bn

Share price return

Finished calendar years

2025202420232022202120202019
Return-0%-37%167%98%-54%199%60%

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.